+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is the most common and aggressive subtype of non-Hodgkin lymphoma NHL, affecting many patients with rapid tumor growth and symptoms depending on tumor location. This observational study aims to understand the clinical characteristics, treatment patterns, and access to new therapies for patients with DLBCL in the Middle East and Africa region, including both newly diagnosed and relapsed or refractory cases. Participants are grouped into two cohorts those who are newly diagnosed and eligible for treatment, and those who have relapsed or are refractory after at least one prior therapy. The study does not involve experimental treatments but collects information on how patients are treated in real-world settings and explores access to innovative therapies. During the study, patient demographics, disease characteristics, risk profiles, and treatment patterns are documented over 22 months. Researchers will gather data through reviews of medical records and clinical information without administering treatments. The primary goal is to describe first-line and subsequent treatment approaches and to understand patient access to novel therapies for DLBCL.

All AgesAll Genders
21 locations
E

Actively Recruiting

This research aims to evaluate the safety and effects of a new medicine called etavopivat in treating pediatric patients with sickle cell disease who are at increased risk for primary stroke. Participants will be grouped based on their transcranial doppler TCD ultrasound results and whether they are taking hydroxyurea, a medication already used for this condition. The study focuses on those with conditional or abnormal TCD results, with the study doctor determining the classification. This is a phase 2, open-label trial designed to assess etavopivats activity on blood flow velocities in key brain arteries. Participants will receive 400 mg of etavopivat orally once daily for a 52-week treatment period. This dose consists of two 200 mg tablets taken with water, with or without food. Participants are divided into two cohorts one receiving etavopivat alone, and another receiving etavopivat in combination with a stable dose of hydroxyurea. After the initial treatment period, there is an optional 48-week extension to further evaluate the safety of etavopivat in pediatric patients. At the studys conclusion, participants may have the option to join a separate study to continue etavopivat treatment. Throughout the study, participants will visit the clinic frequently for assessments, including transcranial doppler ultrasound measurements to track blood flow velocities at various time points. Researchers will monitor changes in the highest time-averaged maximum mean velocities TAMMV in the internal carotid and middle cerebral arteries, as well as the incidence of changes in TCD velocity categories. Safety and treatment effects will be closely observed during both the primary and optional extension periods, with total participation lasting up to 100 weeks if the extension is chosen.

Age: 12Years - 16YearsAll GendersPhase 2
9 locations
L

Actively Recruiting

Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.

Age: 2Years +All GendersPhase 3
107 locations
G

Actively Recruiting

Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.

Age: 12Years +All GendersPhase 3
175 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of inavolisib combined with Phesgo compared to placebo with Phesgo as maintenance treatment after initial therapy in people with untreated HER2-positive advanced breast cancer that has a PIK3CA mutation. This phase III trial focuses on how well the treatments control the disease and their side effects. Participants first receive induction therapy with Phesgo plus taxane-based chemotherapy. Afterward, they receive maintenance therapy with either inavolisib plus Phesgo or placebo plus Phesgo in 21-day cycles. Phesgo is given by subcutaneous injection every 3 weeks, while inavolisib or placebo tablets are taken daily on days 1 to 21 of each cycle. Optional endocrine therapy may also be provided according to standard care. During the study, participants undergo regular assessments including tumor evaluations, heart function tests, laboratory tests, and quality of life questionnaires. Researchers monitor progression-free survival up to about 40 months and overall survival and other outcomes up to approximately 111 months. Participants are followed closely for adverse events and drug levels. The total study duration may extend up to nearly 10 years, with visits scheduled throughout treatment and follow-up periods.

Age: 18Years +All GendersPhase 3
192 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of an Aescin-based herbal extract called Reparil compared with Ibuprofen to manage symptoms after surgical removal of impacted mandibular third molars. This randomized, single-blind controlled trial involves 100 healthy adults aged 18 to 40 years. The goal is to see if Reparil can provide similar pain relief and reduce swelling and limited mouth opening as Ibuprofen, but with fewer side effects. Participants will be randomly assigned to receive either Reparil tablets containing 20 mg Aescin or Ibuprofen 400 mg tablets, both taken orally three times a day for five days after surgery. The surgical procedure and follow-up assessments are standardized. Researchers will measure pain, facial swelling using a 3D scanner, and mouth opening with a digital caliper before surgery and on postoperative days 2 and 7. A rescue pain medication will be available if needed. During the study, participants will attend visits at baseline, day 2, and day 7 after surgery for clinical assessments. Outcomes include changes in pain intensity, facial swelling, mouth opening, and any adverse effects from the medications. Data will be collected and analyzed to evaluate whether the herbal extract offers a safe and effective alternative to conventional nonsteroidal anti-inflammatory drugs in oral surgery.

Age: 18Years - 40YearsAll GendersPhase Not Applicable
1 location
R

Actively Recruiting

Researchers are collecting real-world data in the Gulf Cooperation Council GCC countries on patients with hormone receptor-positive HR-positive, HER2-low or HER2-ultralow metastatic breast cancer mBC who have previously been treated with endocrine therapy. The study evaluates patient characteristics, treatment patterns, survival outcomes, and the safety of Trastuzumab Deruxtecan T-DXd to help optimize treatments and improve outcomes for mBC patients in the region. This observational study follows patients who have started treatment with T-DXd as part of their routine care. Eligible participants include female patients aged 18 years or older with confirmed HR-positive metastatic breast cancer classified as HER2-low or HER2-ultralow, who have received at least one prior line of endocrine therapy but no chemotherapy in the metastatic setting. Patients are observed for up to 18 months to assess treatment patterns and safety. Participants will have their health information collected and monitored, including progression-free survival, time to next treatment, safety profiles, and baseline characteristics. Data is gathered through routine clinical visits without intervention from the study team. The study duration extends through March 2029, allowing for long-term observation of treatment outcomes and patient experiences.

Age: 18Years +FEMALE
9 locations
C

Actively Recruiting

Researchers are evaluating the effect of two different doses of dexamethasone, 4mg and 8mg, given as a submucosal injection to reduce pain after dental implant surgery. The study is a randomized, double-blind, controlled clinical trial that also includes a placebo group receiving normal saline. The goal is to find the best dose of dexamethasone for managing postoperative pain while considering the influence of preoperative anxiety on pain levels. Participants will be randomly assigned to one of three groups receiving 8mg dexamethasone, 4mg dexamethasone mixed with saline, or a placebo injection of saline alone. Each injection is given near the surgical site in the buccal vestibule. The injections are concealed to ensure blinding. The study is planned to start in March 2026 and will follow participants for one week after surgery. During the study, postoperative pain will be measured using a Visual Analog Scale at 6 hours after surgery and daily for the next six days. The number of pain-relief tablets taken will also be recorded during this time. Preoperative anxiety levels will be assessed on the day of surgery using the Generalized Anxiety Disorder-7 questionnaire. The study will monitor these outcomes to determine the effectiveness of the dexamethasone doses in controlling pain after dental implant surgery.

Age: 21Years - 80YearsAll GendersPhase 3
1 location
E

Actively Recruiting

This research investigates the DiaFootCare mobile health application designed to help adults with diabetic foot ulcers manage their self-care and monitor their condition. The study compares the use and effectiveness of DiaFootCare against usual care among patients with diabetic foot ulcers at the National Diabetes and Endocrine Centre in Oman. It aims to understand how this app supports foot self-care, medication adherence, blood sugar control, and wound healing. Participants will be randomly assigned to one of two groups. One group will receive usual diabetic foot care plus access to the DiaFootCare app for three months, which includes educational content, reminders, guided wound photo capture, wound progress tracking, and pharmacist support. The other group will receive the standard diabetic foot care without the app during the same period. Throughout the study, participants will be monitored for wound closure and wound size at multiple time points baseline, and weeks 4, 8, and 12. Researchers will also assess blood sugar control, confidence in foot care, and diabetes self-management skills after three months. Participants will be followed for the duration of the three-month study period to evaluate app engagement and clinical outcomes.

Age: 30Years - 80YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are evaluating the real-world effects of adding anifrolumab to standard treatment for patients with Systemic Lupus Erythematosus SLE. This multi-country observational study aims to gather important information on how anifrolumab works in routine clinical practice across various countries, including those in the Gulf Cooperation Council, Latin America, Taiwan, and Egypt. The study uses standardized criteria and assessments to compare results across these locations. Participants who have been prescribed anifrolumab for the first time will be followed prospectively for one year after their initial infusion. The study also collects data from the year before starting anifrolumab to understand baseline health status. Clinical assessments relevant to SLE, including specific measures for skin symptoms, are used to monitor the patients. The study continues to collect data even if patients stop anifrolumab treatment, unless they withdraw consent. During the study, participants will undergo clinical and patient-reported evaluations at baseline and multiple points over one year, including assessments like PGA, SLEDAI-2K, CLASI, FACIT-Fatigue, LupusQoL, and EQ-5D-5L. Researchers will monitor these outcomes to understand how patients respond to anifrolumab in everyday care. The study period continues until the end of 2027 or until patients discontinue participation, with careful follow-up to capture ongoing health information.

Age: 18Years +All Genders
32 locations

1-10 of 18

1